X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AQEMIA will leverage the net proceeds to accelerate the growth of its wholly-owned pipeline of small molecule drug discovery projects and assets as well as further scale its proprietary GenAI and deep physics drug discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Wendel Growth
Deal Size: $64.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 30, 2024
Details:
Under the collaboration, AQEMIA will design novel drug molecules using its generative AI and deep physics algorithms and platform and Sanofi will leverage its global research and development expertise to accelerate the development of therapeutic drugs.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2023
Details:
Aqemia has employed its unique quantum-physics-inspired artificial intelligence technology to identify innovative, patentable molecules that are experimentally active on an undruggable target in immuno-oncology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
